Eddy Lee was appointed to the Board on 17 January 2008 and is a member of the Nominating Committee. As Group Chairman & CEO, he is responsible for the development and execution of the Group’s strategic vision and expansion plans.
Eddy possesses more than 25 years of international business experience, having worked as Senior Vice President of Resorts World (Genting Group) in Malaysia, Chief Executive of CDL Hotels International Limited (Hong Leong Group) in Hong Kong, President & Chief Executive of Star Cruises PLC (Genting Group) in Singapore and more recently, as Managing Director & Chief Executive of Amcom Telecommunications Limited in Australia.
Eddy is highly regarded as a professional start-up specialist with a very impressive track record in developing companies that have experienced outstanding brand recognition and tremendous growth. He was involved in the successful start-ups of the Burswood Resort Hotel in Perth and Star Cruises PLC in Singapore, and is perhaps best known for successfully introducing, developing and transforming the cruise industry in Asia into a multi-million dollar business today.
Eddy holds a Bachelor of Business degree from Curtin University.
Sien Lup Chew joined iX Biopharma in April 2016. As Chief Financial Officer, Sien Lup oversees the accounting, financial, taxation, investment and other financial matters of the iX Group.
Sien Lup has over 20 years of experience holding senior positions responsible for accounting, audit and treasury matters. He spent more than 9 years with an international public accounting firm serving a variety of clients including those in the energy, utilities and high tech industries. Prior to joining iX, he also served as CFO for Singapore eDevelopment Limited and Metech International Limited, both listed on SGX-ST.
Sien Lup graduated from Monash University, Australia in 1988 with a Bachelor of Economics (Accounting) and a Bachelor of Science (Computer Science) Hons. He has been a Certified Practising Accountant of CPA Australia since 1993.
Dr Janakan Krishnarajah joined iX Biopharma in April 2016. As the Chief Medical Officer, he is responsible for the development and implementation of clinical trial programmes.
Prior to joining iX, Dr Krishnarajah was the CEO and Medical Director of Linear Clinical Research, a leading Australian early phase clinical trials facility. He has extensive experience in phase I-IV clinical trials and has acted as Principal or Co-Investigator in over 100 Phase I/II clinical trials. He is a reviewing panel member of the Clinical Drug Trials Committee at Sir Charles Gairdner Hospital in Western Australia.
Dr Krishnarajah graduated with a Bachelor of Medicine, Bachelor of Surgery (Hons) from The University of Western Australia in 2001. He is a Consultant Physician with specialist interests in Clinical Pharmacology and Internal Medicine.
Dr Iain Cook has more than 30 years of experience in the analysis of complex pharmaceutical and biological samples, with a background in pharmaceutical, veterinary, industrial and agrichemical industries.
Prior to his appointment as Chief Scientist at iX Biopharma, Iain was the director of Chemical Analysis Pty Ltd. He also served as analytical chemist at ICI/Orica, where he specialised in nuclear magnetic resonance and led its Spectroscopy Group (NMR/FTIR/SEM-EDXA/NIR), and at PROBE Analytical thereafter.
Iain obtained his Doctor of Philosophy in Nuclear Magnetic Resonance and Synthetic Organic Chemistry from La Trobe University.
Dr Stephen Lim joined iX Biopharma in July 2017. As Chief Pharmacist of the Group, he participates in new product research and development and assists in clinical trials undertaken by the Group.
Prior to his appointment as Chief Pharmacist, he was an Adjunct Associate Professor in the School of Pharmacy at Curtin University and has more than 34 years experience in the hospital and commercial pharmacy sectors.
Dr Lim is also an expert in drug formulation and stability. He completed his Master thesis by looking at drug stability in the frozen state and has shown that intranasal fentanyl delivery is as effective as intravenous fentanyl.
Dr Lim obtained a Bachelor of Pharmacy (with distinctions), a Master of Pharmacy and a Ph.D. in Pharmacy in novel drug delivery systems from Curtin University.
As Commercial Director, Ms Eva Tan oversees the commercial, legal and corporate matters of the iX Group.
Prior to joining iX, Eva was a corporate lawyer at Wong Partnership, a leading law firm in Singapore, where she specialised in the capital markets practice. Eva was involved in numerous local and international IPOs, including the listing of iX Biopharma Ltd on the SGX Catalist in 2015. She has also had extensive experience advising on a broad range of local and cross border mergers and acquisitions and other corporate transactions.
Eva obtained her LLB from the National University of Singapore and was admitted to the Singapore Bar in 2008.
Desiree Chua is responsible for the business development and marketing activities of the Group’s products in the Asia Pacific region. These include product branding, regulatory affairs, and market research activities. She was previously a management consultant at PricewaterhouseCoopers Singapore before joining iX Biopharma in September 2015.
Desiree obtained her degrees in Bachelor of Business Management and Bachelor of Accountancy at Singapore Management University.